MedTrace Logo

Reduction of Oxygen After Cardiac Arrest

NCT03138005 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 428

Last updated 2025-10-02

No results posted yet for this study

Summary

The Reduction of oxygen after cardiac arrest (EXACT) is a multi-centre, randomised, controlled trial (RCT) to determine whether reducing oxygen administration to target an oxygen saturation of 90-94%, compared to 98-100%, as soon as possible following successful resuscitation from OHCA improves outcome at hospital discharge.

Conditions

  • Out-of-Hospital Cardiac Arrest

Interventions

OTHER

target SpO2 98-100%

Prehospital, post-ROSC oxygen maintained at ≥10L/minute of oxygen (equivalent to \~100% oxygen) into SGA/ETT if hand ventilated or 100% (i.e. FiO2 of 1.0) oxygen settings if mechanically ventilated. Patients will continue on treatment to handover in the ED. Between arrival at ED and first ABG in ICU, the oxygen setting may then be decreased provided SpO2 is maintained between 98-100%.

OTHER

target SpO2 90-94%

Prehospital, post-ROSC oxygen reduced initially to 4L/minute (i.e. approximately 70% oxygen) into SGA/ETT if hand ventilated or an air mix setting if mechanically ventilated. If oxygen saturation remains ≥94% for 5 minutes, the oxygen flow rate will be further reduced to 2L/minute (i.e. approximately 46% oxygen) and hand ventilated to target an oxygen saturation between 90-94%. This treatment will continue to patient handover in the emergency department. Between arrival at ED and first ABG in ICU, oxygen will be titrated to target a oxygen saturation of 90-94%.

Sponsors & Collaborators

  • Ambulance Victoria

    collaborator OTHER_GOV

  • SA Ambulance Service

    collaborator UNKNOWN

  • St John Ambulance Australia (Western Australia)

    collaborator UNKNOWN

  • Flinders University

    collaborator OTHER

  • Curtin University

    collaborator OTHER

  • Monash University

    lead OTHER

Principal Investigators

  • Stephen Bernard · Ambulance Victoria

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-11
Primary Completion
2020-08-05
Completion
2020-08-05

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03138005 on ClinicalTrials.gov